Risankizumab

  • Part D specialty tier in 80% of formularies (2026Q3)
  • Biologic
  • Skyrizi

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Risankizumab: storage and handling

Refrigerate
Yes, as the label states
Label statement
Store in a refrigerator at 36°F to 46° F (2°C to 8°C).
Freezing
Do not freeze
Label statement
Do not freeze.
Room temperature
No allowance stated
Back into the refrigerator
Not addressed
Light
Protect from light
Label statement
Keep in the original cartons to protect from light.
Shaking
Do not shake
Label statement
Do not shake.

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

The label does not state a room-temperature allowance for this product.

Entered: 1 day at up to 77°F (25°C).

Store in a refrigerator at 36°F to 46° F (2°C to 8°C).
Do not freeze.

Contact the manufacturer about this product; the label text ClinDose has does not print a phone number for it.

All storage statements on the label (8)
  • Store in a refrigerator at 36°F to 46° F (2°C to 8°C).
  • Do not freeze.
  • Do not shake.
  • Keep in the original cartons to protect from light.
  • Information Store SKYRIZI Pen in the refrigerator between 36°F to 46°F (2°C to 8°C).
  • Keep SKYRIZI Pen in the original carton to protect from light until you are ready to use.
  • Do not use SKYRIZI Pen if the liquid has been frozen, even if it has been thawed.
  • Do not shake SKYRIZI Pen.

FDA label version 179, effective June 15, 2026. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

98%of plans list it
98%of those: prior authorization
0%step therapy
95%quantity limit
97%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

No manufacturer program page is listed for this drug yet.

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.